0001209191-23-052048.txt : 20231004 0001209191-23-052048.hdr.sgml : 20231004 20231004172838 ACCESSION NUMBER: 0001209191-23-052048 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231002 FILED AS OF DATE: 20231004 DATE AS OF CHANGE: 20231004 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: PRENDERGAST FRANKLYN G CENTRAL INDEX KEY: 0001233256 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39580 FILM NUMBER: 231308998 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Immunome Inc. CENTRAL INDEX KEY: 0001472012 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770694340 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 665 STOCKTON DRIVE STREET 2: SUITE 300 CITY: EXTON STATE: PA ZIP: 19341 BUSINESS PHONE: 610-321-3700 MAIL ADDRESS: STREET 1: 665 STOCKTON DRIVE STREET 2: SUITE 300 CITY: EXTON STATE: PA ZIP: 19341 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-10-02 0 0001472012 Immunome Inc. IMNM 0001233256 PRENDERGAST FRANKLYN G C/O IMMUNOME, INC. 665 STOCKTON DRIVE, SUITE 300 EXTON PA 19341 1 0 0 0 0 Common Stock 2023-10-02 4 A 0 60840 0.00 A 60840 D Stock Option (Right to Buy) 1.35 2023-10-02 4 A 0 137725 1.35 A 2032-09-26 Common Stock 137725 137725 D In connection with the Closing (as defined in the Agreement and Plan of Merger and Reorganization dated June 29, 2023 (the "Merger Agreement"), by an among the Issuer, Ibiza Merger Sub, Inc., and Morphimmune Inc.), Dr. Prendergast exchanged (i) his shares of common stock of Morphimmune for shares of the Issuer and (ii) his options to acquire shares of common stock of Morphimmune for options to acquire shares of the Issuer. In connection with the Closing (as defined in the Merger Agreement), all the shares underlying the option became fully vested and exercisable. /s/ Sandra Stoneman, Attorney-in-Fact 2023-10-02